Identification

Name
Cangrelor
Accession Number
DB06441
Type
Small Molecule
Groups
Approved
Description

Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.

Structure
Thumb
Synonyms
  • [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
External IDs
AR-C69931XX / AR69931
Product Ingredients
IngredientUNIICASInChI Key
Cangrelor tetrasodium2144G00Y7W163706-36-3COWWROCHWNGJHQ-OPKBHZIBSA-J
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
KengrealInjection, powder, lyophilized, for solution50 mg/1IntravenousChiesi Pharmaceuticals Inc.2015-07-08Not applicableUs
KengrealInjection, powder, lyophilized, for solution50 mg/1IntravenousThe Medicines Company2015-07-08Not applicableUs
KengrexalInjection, powder, for solution50 mgIntravenousChiesi Farmaceutici S.P.A.2015-03-23Not applicableEu
Categories
UNII
6AQ1Y404U7
CAS number
163706-06-7
Weight
Average: 776.35
Monoisotopic: 774.9483145
Chemical Formula
C17H25Cl2F3N5O12P3S2
InChI Key
PAEBIVWUMLRPSK-IDTAVKCVSA-N
InChI
InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1
IUPAC Name
[dichloro({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-{[2-(methylsulfanyl)ethyl]amino}-2-[(3,3,3-trifluoropropyl)sulfanyl]-9H-purin-9-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl})methyl]phosphonic acid
SMILES
CSCCNC1=C2N=CN([[email protected]@H]3O[[email protected]](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[[email protected]@H](O)[[email protected]]3O)C2=NC(SCCC(F)(F)F)=N1

Pharmacology

Indication

For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Cangrelor is a selective, reversible, P2Y12 platelet receptor antagonist which inhibits ADP platelet aggregation. ADP is typically released by damaged blood vessels, red blood cells, and/or platelets due to agonists stimulating platelet activity. ADP binds to P2Y12 to stimulate and complete platelet aggregation by inhibiting adenylyl cyclase by a Gi protein, thus potentiating dense granule secretion and increasing coagulation activity. Cangrelor acts on the same target as oral irreversible inhibitors clopidogrel and ticlopidine and has a similar mechanism of action, but is reversible and provides a fast onset and offset of action.

TargetActionsOrganism
AP2Y purinoceptor 12
inhibitor
Human
Absorption
Not Available
Volume of distribution

In a study in healthy volunteers administration at a dose of 30 mcg/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L.

Protein binding

about 97-98%.

Metabolism

Cangrelor is deactivated rapidly in the circulation by dephosphorylation to its primary metabolite, a nucleoside, which has negligible anti-platelet activity. Cangrelor's metabolism is independent of hepatic function and it does not interfere with other drugs metabolized by hepatic enzymes.

Route of elimination

Following IV administration of [3H] cangrelor, 58% of radioactivity was recovered in urine. The remaining 35% of radioactivity was in feces, presumably following biliary excretion.

Half life

The average elimination half-life of cangrelor is about 3-6 minutes.

Clearance

The mean clearance is about 43.2 L/h.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabCangrelor may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolCangrelor may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Cangrelor is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Cangrelor is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Cangrelor.Approved, Investigational
AlteplaseCangrelor may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Cangrelor is combined with Aminosalicylic Acid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Cangrelor.Approved
AncrodCangrelor may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Cangrelor.Investigational
AnistreplaseCangrelor may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanCangrelor may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Cangrelor is combined with Apixaban.Approved
AprotininThe therapeutic efficacy of Cangrelor can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinCangrelor may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanCangrelor may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinCangrelor may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the anticoagulant activities of Cangrelor.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Cangrelor is combined with Balsalazide.Approved, Investigational
BatroxobinCangrelor may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminCangrelor may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinCangrelor may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Cangrelor.Investigational
BivalirudinCangrelor may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseCangrelor may increase the anticoagulant activities of Brinase.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Cangrelor.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Cangrelor.Investigational
CaplacizumabCangrelor may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Cangrelor is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinCangrelor may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolCilostazol may increase the anticoagulant activities of Cangrelor.Approved, Investigational
Citric AcidCangrelor may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelCangrelor may decrease the antiplatelet activities of Clopidogrel.Approved
CloricromenCangrelor may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneCangrelor may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Cangrelor is combined with Collagenase clostridium histolyticum.Approved, Investigational
Dabigatran etexilateCangrelor may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinCangrelor may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCangrelor may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanCangrelor may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Cangrelor.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Cangrelor.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Cangrelor is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Cangrelor is combined with Dersalazine.Investigational
DesirudinCangrelor may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseCangrelor may increase the anticoagulant activities of Desmoteplase.Investigational
DextranCangrelor may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DicoumarolCangrelor may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Cangrelor is combined with Diflunisal.Approved, Investigational
DiphenadioneCangrelor may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Cangrelor.Approved
DitazoleCangrelor may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaCangrelor may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidCangrelor may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCangrelor may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinCangrelor may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Cangrelor.Approved, Investigational
EplivanserinCangrelor may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Cangrelor.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Cangrelor.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Cangrelor.Approved, Investigational
Ethyl biscoumacetateCangrelor may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidCangrelor may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinCangrelor may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneCangrelor may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxCangrelor may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumCangrelor may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateCangrelor may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Cangrelor.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Cangrelor is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Cangrelor is combined with Hemoglobin crosfumaril.Experimental
HeparinCangrelor may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineCangrelor may increase the anticoagulant activities of Higenamine.Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Cangrelor.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Cangrelor.Approved
IbudilastIbudilast may increase the anticoagulant activities of Cangrelor.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Cangrelor.Approved, Investigational, Nutraceutical
IdraparinuxCangrelor may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Cangrelor.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Cangrelor.Investigational
IloprostIloprost may increase the anticoagulant activities of Cangrelor.Approved, Investigational
IndobufenCangrelor may increase the anticoagulant activities of Indobufen.Investigational
KetanserinKetanserin may increase the anticoagulant activities of Cangrelor.Investigational
LepirudinCangrelor may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanCangrelor may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Cangrelor.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Cangrelor.Experimental
MelagatranCangrelor may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Cangrelor is combined with Mesalazine.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Cangrelor is combined with Methyl salicylate.Approved, Vet Approved
MilrinoneMilrinone may increase the anticoagulant activities of Cangrelor.Approved
NadroparinCangrelor may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatCangrelor may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Cangrelor.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Cangrelor.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Cangrelor is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Cangrelor is combined with Obinutuzumab.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Cangrelor is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Cangrelor.Approved, Nutraceutical
OtamixabanCangrelor may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelCangrelor may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinCangrelor may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateCangrelor may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cangrelor.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Cangrelor.Approved, Investigational
PhenindioneCangrelor may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCangrelor may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Cangrelor is combined with Phenyl aminosalicylate.Approved
PicotamideCangrelor may increase the anticoagulant activities of Picotamide.Experimental
PrasugrelCangrelor may decrease the antiplatelet activities of Prasugrel.Approved
Protein CCangrelor may increase the anticoagulant activities of Protein C.Approved
Protein S humanCangrelor may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCangrelor may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Cangrelor.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Cangrelor.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Cangrelor.Approved, Experimental, Investigational
ReteplaseCangrelor may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinCangrelor may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Cangrelor.Approved
RivaroxabanCangrelor may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneCangrelor may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Cangrelor is combined with Salicylic acid.Approved, Investigational, Vet Approved
SarpogrelateCangrelor may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseCangrelor may increase the anticoagulant activities of Saruplase.Experimental
SelexipagCangrelor may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Cangrelor.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Cangrelor.Investigational
StreptokinaseCangrelor may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideCangrelor may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseCangrelor may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Cangrelor.Investigational
TicagrelorCangrelor may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Cangrelor.Approved
TinzaparinCangrelor may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolCangrelor may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Cangrelor.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Cangrelor.Approved
TositumomabThe risk or severity of adverse effects can be increased when Cangrelor is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Cangrelor.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Cangrelor.Approved
TreprostinilCangrelor may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TriflusalCangrelor may increase the anticoagulant activities of Triflusal.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Cangrelor is combined with Trolamine salicylate.Approved
TroxerutinCangrelor may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseCangrelor may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Cangrelor.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Cangrelor.Approved
WarfarinCangrelor may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCangrelor may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
  1. Keating GM: Cangrelor: A Review in Percutaneous Coronary Intervention. Drugs. 2015 Aug;75(12):1425-34. doi: 10.1007/s40265-015-0445-3. [PubMed:26201463]
  2. Fugate SE, Cudd LA: Cangrelor for treatment of coronary thrombosis. Ann Pharmacother. 2006 May;40(5):925-30. Epub 2006 Apr 4. [PubMed:16595568]
External Links
KEGG Drug
D03359
PubChem Compound
9854012
PubChem Substance
310264872
ChemSpider
8029718
BindingDB
50118225
ChEBI
90841
ChEMBL
CHEMBL334966
PharmGKB
PA165945763
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cangrelor
ATC Codes
B01AC25 — Cangrelor
FDA label
Download (520 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1RecruitingPreventionComplete Obstruction of Systemic to Pulmonary Artery Shunt / Partial Obstruction of Systemic to Pulmonary Artery Shunt1
2CompletedNot AvailableCoronary Artery Disease2
2CompletedBasic ScienceCoronary Artery Disease1
2CompletedTreatmentAcute Coronary Syndromes (ACS)1
2CompletedTreatmentStable Angina (SA)1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Atherosclerosis1
3TerminatedTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction (MI)1
4Not Yet RecruitingTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction (MI) / ST Elevation Myocardial Infarction (STEMI)1
4Not Yet RecruitingTreatmentCoronary Artery Disease / ST Elevation Myocardial Infarction (STEMI)1
4RecruitingTreatmentACS - Acute Coronary Syndrome / Cardiopulmonary Arrest With Successful Resuscitation / Hypothermia, Induced1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / High On-treatment Platelet Reactivity (HTPR) / Microvascular Obstruction (MVO) / ST Segment Elevation Myocardial Infarction (STEMI) / Thrombolysis in Myocardial Infarction (TIMI) / Unstable Angina (UA)1
4RecruitingTreatmentPercutaneous Coronary Intervention / ST Segment Elevation Myocardial Infarction (STEMI)1
Not AvailableRecruitingNot AvailableNon-ST Elevation Myocardial Infarction (NSTEMI)1
Not AvailableRecruitingTreatmentST Elevation Myocardial Infarction (STEMI)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous50 mg/1
Injection, powder, for solutionIntravenous50 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6130208No1998-06-292018-06-29Us
US6114313No1997-12-112017-12-11Us
US8680052No2013-03-092033-03-09Us
US8759316No2009-05-132029-05-13Us
US9295687No2015-07-102035-07-10Us
US9439921No2015-07-102035-07-10Us
US9427448No2010-11-102030-11-10Us
US9700575No2015-07-102035-07-10Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.33 mg/mLALOGPS
logP1.21ALOGPS
logP-0.12ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)0.8ChemAxon
pKa (Strongest Basic)2.61ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area255.91 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity153.78 m3·mol-1ChemAxon
Polarizability63.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine ribonucleoside monophosphates. These are nucleotides consisting of a purine base linked to a ribose to which one monophosphate group is attached.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleotides
Sub Class
Purine ribonucleotides
Direct Parent
Purine ribonucleoside monophosphates
Alternative Parents
Pentose phosphates / 6-alkylaminopurines / Glycosylamines / Monosaccharide phosphates / Bisphosphonates / Alkylarylthioethers / Aminopyrimidines and derivatives / Secondary alkylarylamines / Monoalkyl phosphates / N-substituted imidazoles
show 18 more
Substituents
Purine ribonucleoside monophosphate / Pentose phosphate / Pentose-5-phosphate / Glycosyl compound / N-glycosyl compound / 6-alkylaminopurine / 6-aminopurine / Monosaccharide phosphate / Bisphosphonate / Imidazopyrimidine
show 46 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name
P2RY12
Uniprot ID
Q9H244
Uniprot Name
P2Y purinoceptor 12
Molecular Weight
39438.355 Da
References
  1. Gan XD, Wei BZ, Fang D, Fang Q, Li KY, Ding SL, Peng S, Wan J: Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. Curr Med Res Opin. 2015 Dec;31(12):2313-23. doi: 10.1185/03007995.2015.1098600. Epub 2015 Nov 4. [PubMed:26402735]

Drug created on March 19, 2008 10:33 / Updated on May 02, 2018 01:27